25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue The Lancet Haematology Année : 2022

25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial

Violaine Jabbour
  • Fonction : Auteur
Herve Guenneguez
  • Fonction : Auteur
Pierre Ouvry
  • Fonction : Auteur
François Verrière
  • Fonction : Auteur
Olivier Pichot
  • Fonction : Auteur
Mario Maufus
  • Fonction : Auteur
Hervé Guenneguez
  • Fonction : Auteur
Pierre Ouvry
  • Fonction : Auteur
Anna Di Maio
  • Fonction : Auteur
Jeannot Schmidt
  • Fonction : Auteur
Jean-Philippe Galanaud
  • Fonction : Auteur
Alessandra Bura-Rivière
  • Fonction : Auteur
Francis Couturaud
  • Fonction : Auteur
Marc Danguy Des Déserts
  • Fonction : Auteur
Claire Grange
  • Fonction : Auteur
Patrick Mismetti
  • Fonction : Auteur
Marie-Thérèse Barrellier
  • Fonction : Auteur
Damien Laneelle
  • Fonction : Auteur
Béatrice Terriat
  • Fonction : Auteur
Audrey Stansal
  • Fonction : Auteur
Myriam Martin
  • Fonction : Auteur
Constant Quashie
  • Fonction : Auteur
Mickaël Bonaldi
  • Fonction : Auteur
Patrick Lanoye
  • Fonction : Auteur
Francine Ponchaux-Crépin
  • Fonction : Auteur
Toufek Berremili
  • Fonction : Auteur
Santhi Samy-Modeliar
  • Fonction : Auteur
Azeddine Addala
  • Fonction : Auteur
Luc Toffin
  • Fonction : Auteur
Bruno Rouquet
  • Fonction : Auteur
Maïlys Michot-Casbas
  • Fonction : Auteur
Guillaume Lacaze
  • Fonction : Auteur
Pierre-Marie Roy
  • Fonction : Auteur
Cécile Durant
  • Fonction : Auteur
Anne-Laure Baldassini-Esquis
  • Fonction : Auteur
Alain Cazanave
  • Fonction : Auteur
Damien Rouvière
  • Fonction : Auteur
Hélène Skolka
  • Fonction : Auteur
Tewfik Salem
  • Fonction : Auteur
Jean-Michel Monsallier
  • Fonction : Auteur
Benoit Roger
  • Fonction : Auteur
Thien-Quang Tra
  • Fonction : Auteur
Mutendi Kalolwa
  • Fonction : Auteur
Antoine Diard
  • Fonction : Auteur
Marc Lambert
  • Fonction : Auteur
Mebarka Taiar
  • Fonction : Auteur
Céline Gaudout
  • Fonction : Auteur
Sylvain Ancey
  • Fonction : Auteur
Christine Jurus
  • Fonction : Auteur

Résumé

Background: The optimal strength of compression needed to prevent post-thrombotic syndrome (PTS) after a proximal deep vein thrombosis (DVT) is debated. We aimed to assess whether 25 mm Hg elastic compression stockings (ECS) are non-inferior to 35 mm Hg ECS in preventing PTS after a DVT. Methods: In this multicentre, double-blind, non-inferiority, randomised controlled trial, we enrolled adults (≥18 years) with a first ipsilateral proximal DVT attending 46 French vascular medicine hospital departments or private practices. Participants were randomly allocated (1:1, stratified by centre, age, and sex; with varying block sizes of two and four) to wear 25 mm Hg or 35 mm Hg ECS for 2 years. The primary outcome was the cumulative rate of PTS 2 years after inclusion, defined by a Villalta scale (≥5). Efficacy was assessed by intention-to-treat and in eligible participants who had complete primary outcome data. A per-protocol analysis was also conducted among compliant patients as a secondary outcome measure. Safety was assessed in all participants who used ECS at least once, and for which we have at least some tolerance information during follow-up. The margin for non-inferiority was 12·5%. This study is registered with ClinicalTrials.gov, NCT01578122, and has been completed. Findings: Between June 28, 2012, and July 21, 2017, we enrolled 341 eligible participants who consented to randomisation. 233 (68%) were men and median age was 59 years (IQR 45-70). Collection of ethnicity and race as a routine research variable is not authorised in France. Median follow-up was 735 days (IQR 721-760). 249 (73%) had complete data at 2 years. For the primary analysis, 40 (31%) of 129 participants with complete data in the 25 mm Hg ECS group and 40 (33%) of 120 in the 35 mm Hg group had PTS (absolute difference -2·3% [90% CI -12·1 to 7·4], pnon-inferiority=0·0062; relative risk 0·93, 95% CI 0·65 to 1·33). Results remained similar after imputation of missing data in patients we were authorised to do so: the cumulative proportion of PTS was 45 (29%) of 154 in the 25 mm Hg ECS group versus 52 (35%) of 148 in the 35 mm Hg ECS group (relative risk 0·83, 95% CI 0·60 to 1·16). Absolute difference was -5·9%, (90% CI -14·7 to 2·9), p=0·0003 for non-inferiority. Adherence was optimal (>80% and modified GIRERD score of 0-2) for 75 (51%) of 146 patients assigned to 25 mm Hg ECS and for 56 (42%) of 134 patients assigned to 35 mm Hg ECS (p=0·11). Regarding major adverse events related to ECS, there were no between-group differences in rates of deep vein thrombosis (0 vs 1 [0·6%]), ipsilateral leg ulcer (0 vs 1 [0·6%]), infection (0 vs 0), or death (0 vs 0) between the 169 patients evaluated in the 25 mm Hg ECS group and the 159 patients in the 35 mm Hg ECS group. Two (1%) of 328 patients who ever wore ESC developed ECS-related serious adverse events, one distal DVT and one leg ulcer (both in the 35 mm Hg ECS group). In the 25 mm Hg group, 6 patients died, 14 had a venous thromboembolic recurrence (proximal DVT or pulmonary embolism), and 7 had a major bleed. In the 35 mm Hg group, 5 patients died, 10 had a venous thromboembolic recurrence (proximal DVT or pulmonary embolism), and 6 had a major bleed. Interpretation: Although we did not reach the prespecified sample size, our results suggest that 25 mm Hg ECS are non-inferior to 35 mm Hg ECS in preventing PTS. Larger more powerful studies are needed.
Fichier non déposé

Dates et versions

hal-03890237 , version 1 (08-12-2022)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Jean-Philippe Galanaud, Céline Genty-Vermorel, Marie-Thérèse Barrellier, François Becker, Violaine Jabbour, et al.. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial. The Lancet Haematology, 2022, 9 (12), pp.e886-e896. ⟨10.1016/S2352-3026(22)00247-2⟩. ⟨hal-03890237⟩
1748 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More